-transparent.png){kind=logo}
Three patients with leukemia developed corneal toxicity while receiving high doses (3 g/m2) of systemic cytarabine. Symptoms began five to seven days after initiation of treatment with high doses of systemic cytarabine and consisted of ocular pain, tearing, foreign-body sensation, photophobia, and blurred vision. All three patients developed bilateral conjunctival hyperemia and fine corneal epithelial opacities and refractile microcysts that were more numerous in the central than in the peripheral cornea. The symptoms disappeared without treatment in approximately one week. The corneal changes we observed with high doses of systemic cytarabine resembled descriptions of corneal toxicity from topical cytarabine and were probably secondary to inhibition of DNA synthesis in the corneal epithelium.
G Hopen, and
B J Mondino, and
B L Johnson, and
P A Chervenick
July 2003,
Eye (London, England),
G Hopen, and
B J Mondino, and
B L Johnson, and
P A Chervenick
April 2013,
Annals of hematology,
G Hopen, and
B J Mondino, and
B L Johnson, and
P A Chervenick
March 2023,
BMC ophthalmology,
G Hopen, and
B J Mondino, and
B L Johnson, and
P A Chervenick
January 1989,
Ophtalmologie : organe de la Societe francaise d'ophtalmologie,
G Hopen, and
B J Mondino, and
B L Johnson, and
P A Chervenick
January 2024,
Clinical & experimental optometry,
G Hopen, and
B J Mondino, and
B L Johnson, and
P A Chervenick
November 1982,
American journal of ophthalmology,
G Hopen, and
B J Mondino, and
B L Johnson, and
P A Chervenick
March 1979,
Klinika oczna,
G Hopen, and
B J Mondino, and
B L Johnson, and
P A Chervenick
December 2006,
Cornea,
G Hopen, and
B J Mondino, and
B L Johnson, and
P A Chervenick
January 1990,
Drug safety,
G Hopen, and
B J Mondino, and
B L Johnson, and
P A Chervenick
January 1992,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
